Dwight Morrow was thrilled to land a job at Moderna in June 2023 after its blockbuster Covid-19 vaccine had turned the once-obscure Cambridge biotech into a household name. Morrow, a molecular and ...
Moderna is deprioritizing its flu/COVID combination vaccine in younger adults amid a push to cut around $1.5 billion from its operating expenses. The biotech disclosed the changes alongside news of a ...
In the early days of the COVID-19 pandemic, Moderna (NASDAQ: MRNA) was a top performer, from both a share-price and an earnings perspective. As one of the leading coronavirus vaccine companies, the ...
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...
Shares in Moderna and BioNTech have imploded since their 2021 peaks, shaving billions of dollars from their founders’ fortunes. Growing anti-vax hysteria and RFK Jr.’s FDA will likely make the ...
Hosted on MSN
Down 80%, should you buy the dip on Moderna?
Moderna’s earnings and stock price climbed during early pandemic days -- that’s as demand for the company’s coronavirus vaccine soared. Since, the company has faced various challenges that have ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback